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Abstract
Background: Spinal muscular atrophy (SMA) is the most common neuromuscular autosomal recessive disorder. The
American College of Medical Genetics has recently recommended routine carrier screening for SMA because of the high
carrier frequency (1 in 25–50) as well as the severity of that genetic disease. Large studies are needed to determine the
feasibility, benefits, and costs of such a program.
Methods and Findings: This is a prospective population-based cohort study of 107,611 pregnant women from 25 counties
in Taiwan conducted during the period January 2005 to June 2009. A three-stage screening program was used: (1) pregnant
women were tested for SMA heterozygosity; (2) if the mother was determined to be heterozygous for SMA (carrier status),
the paternal partner was then tested; (3) if both partners were SMA carriers, prenatal diagnostic testing was performed.
During the study period, a total of 2,262 SMA carriers with one copy of the SMN1 gene were identified among the 107,611
pregnant women that were screened. The carrier rate was approximately 1 in 48 (2.10%). The negative predictive value of
DHPLC coupled with MLPA was 99.87%. The combined method could detect approximately 94% of carriers because most of
the cases resulted from a common single deletion event. In addition, 2,038 spouses were determined to be SMA carriers.
Among those individuals, 47 couples were determined to be at high risk for having offspring with SMA. Prenatal diagnostic
testing was performed in 43 pregnant women (91.49%) and SMA was diagnosed in 12 (27.91%) fetuses. The prevalence of
SMA in our population was 1 in 8,968.
Conclusion: The main benefit of SMA carrier screening is to reduce the burden associated with giving birth to an affected
child. In this study, we determined the carrier frequency and genetic risk and provided carrier couples with genetic services,
knowledge, and genetic counseling.
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Introduction
The main purpose of carrier screening is to identify asymptom-
atic carrier couples with no family history who are at risk for
offspring with a specific genetic disease. Recently, the American
College of Medical Genetics recommended routine carrier
screening for spinal muscular atrophy (SMA) in the general
population because of its high carrier frequency and the severity of
the genetic disease [1].
Proximal SMA is the most common autosomal recessive
neurodegenerative disorder. This severe neuromuscular disease
affects 1 in 5,000 to 1 in 10,000 live births and is associated with
an overall carrier frequency of 1 in 35 to 1 in 50 in the general
population [2,3,4,5]. SMA is caused by degeneration and loss of
the alpha motor neurons of the anterior horn cells of the spinal
cord, leading to progressive symmetric proximal muscle weakness
and atrophy [6]. Currently, there is no treatment for the disease
[6]. Type I SMA (Werdnig-Hoffman disease, OMIM 253300)
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e17067manifests as severe muscle weakness and hypotonia with onset in
early infancy, and fatal respiratory failure usually before 2 years of
age. Type II SMA (intermediate, OMIM 253550) is characterized
by onset before 18 months of age, an ability to sit but not to walk
unaided, and survival beyond 4 years of age. Type III SMA
(Kugelberg-Welander disease, OMIM 253400) is a mild form with
onset in late childhood and survival into adulthood. Type IV SMA
(OMIM 271150) is an adult form, with onset at 35 years of age or
older.
All clinical forms of SMA map to chromosome 5q13, a region
that contains two survival motor neuron (SMN) genes that
compromise two nearly identical copies, a centromeric copy of
the survival motor neuron 2 (SMN2) gene and a telomeric copy of
the survival motor neuron 1 (SMN1) gene [7]. The SMN1 gene
contributes more than 90% of the functionality of the SMN
protein [8]. A point mutation in exon 7, a C to T substitution,
creates an exonic splicing silencer or disrupts an exonic slicing
enhancer [9,10], leading to an SMN2 gene product with a
truncated SMN protein lacking exon 7. Mutations in the SMN1
gene result in reduction of survival of the SMN protein, which
leads to various severities of clinical SMA. More than 94% of
typical SMA patients have homozygous absence of the SMN1
gene, which occurs by deletion or conversion to the SMN2 gene,
with absence of exon 7 or both exons 7 and 8 [11]. The SMN2
copy number leads to variable phenotypes and severities of SMA,
ranging from symptomatic disease in early childhood to
asymptomatic disease, and the varying clinical phenotypes
correlate with the copy number of SMN2 [12,13].
Carrier screening for Tay-Sachs disease in Ashkenazi Jews has
been offered since 1969 [14], and the screening programs have led
to a marked reduction in the incidence of Tay-Sachs disease in
that population. More broad-based population carrier testing for
cystic fibrosis and Gaucher disease has been offered in New York
since 1994 and in Israel since 1995 [15,16]. Criteria for carrier
screening for a genetic disorder generally include clinical severity,
high carrier frequency, a reliable and cost-effective testing
platform, and availability of genetic counseling for carrier couples
[17]. Population-based preconception and prenatal carrier
screening for SMA should be made available on a routine basis
because of its incidence and severity, high carrier frequency rate,
and the availability of a screening test by quantitative polymerase
chain reaction or hybridization-based approaches [18,19,20].
Although there are many strategies for estimating SMN1 allele
frequency [21,22,23,24,25], population-based carrier screening is
controversial because no pilot studies have been conducted. It is,
therefore, critical to provide population-based genetic screening of
SMA carriers.
We, therefore, performed a nationwide SMA carrier genetic
screening study using two different assay methods. Denaturing
high-performance liquid chromatography (DHPLC) and multiplex
ligation-dependent probe amplification (MLPA) [26] were used to
detect the presence of SMN1 and SMN2 among a cohort of
107,611 individuals from 25 counties in Taiwan during the period
January 2005 to June 2009. A three-stage screening program was
used: (1) pregnant women were tested for SMA heterozygosity; (2)
if a woman was heterozygous for SMA (carrier status), the paternal
partner was then tested; and (3) if both partners were SMA
carriers, prenatal diagnostic testing was performed.
Materials and Methods
Sample Collection
Individuals were enrolled into the study after providing
written informed consent to participate in the SMA-carrier
screening program. This study was approved by the Institu-
tional Review Board and Research Ethics Committee of the
National Taiwan University Hospital. All individuals were
given a written information datasheet about SMA carrier
screening. Potential participants were provided with a brief
explanation of SMA history, the genetics of SMA, an overview
of inheritance, and information on the estimated carrier
frequency in the general population, the availability of carrier
testing, and the benefits, costs, and limitations of genetic
counseling. All subjects were informed that confidentiality
would be maintained. The individuals were given a choice to
participate in SMA carrier testing and retained the right to
refuse participation at any time during the study. The
demographic characteristics of the pregnant women recruited
into the study are listed in Table 1.
Three-stage Screening
We used a three-stage screening process to estimate the
prevalence and define the characteristics of SMA in Taiwan.
During the first-stage screening, a total of 107,611 pregnant
women were recruited from 383 primary clinics located in 25
counties. There were 163 (42.6%) clinics located in northern
Taiwan, 103 (26.9%) located in central Taiwan, 97 (25.3%)
located in southern Taiwan, and 20 (5.2%) located in eastern
Taiwan. During the second-stage screening process, 2,038 spouses
or partners were screened. High-risk couples were assigned to
complete the third-stage diagnostic assessment with the genetic
counseling. Prenatal diagnostic testing was performed in 47
women.
Genetic Counseling
The counseling team consisted of medical geneticists, genetic
counselors, social workers, and pediatric neurologists. The genetic
counselors were available anytime on line to give more
information.
(a) Pretest counseling. Each hospital or clinic informed
pregnant women of the SMA study using an information
datasheet and brochures. The physicians of these units were
personally contacted and educated by our counseling team. The
information datasheet offered women basic information on
SMA, carrier frequency, autosomal recessive inheritance,
sensitivity, outcomes, effects, and limitations. The call for
participants was sent in regard to a national study on carrier
screening for SMA, and participants were informed by each
center’s physician. Moreover, the participant’s confidentiality
was maintained and the results of genetic testing were reviewed
and signed by a geneticist at the National Taiwan University
Hospital.
(b) Interpretation of results. Provision of results is an
important component of genetic counseling. When a pregnant
woman was identified as being heterozygous for SMA upon
screening, the couple was referred for genetic counseling.
Moreover, the paternal partner was asked to undergo SMA
carrier testing. If both partners were identified as a carrier
couple, we provided face-to-face genetic counseling and
explained the options for invasive prenatal genetic diagnostic
testing of the fetus, either by chorionic villus sampling (CVS)
or amniocentesis. The couples were also told that they also
had the right to refuse participation at any point in the
study.
(c) Posttest counseling. If the prenatal diagnostic testing
results were negative for SMA, the counselors explained to the
couple that the result could be a false-negative result. If the
prenatal diagnostic testing results confirmed that the fetus had
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counseling center. Couples were informed of the different
management decisions available and were asked for permission
to perform genetic testing of their existing children, if any, born
before the SMA screening.
DNA extraction
After having undergone genetic counseling and obtaining
informed consent for participation during the pretest period,
genomic DNA was extracted from peripheral whole blood using
the Chemagic DNA Blood Kit (Chemagen, Worcester, MA,
USA), according to the manufacturer’s instructions.
Multiplex Polymerase Chain Reaction and DHPLC Analysis
Deletions or conversions of the SMN1 gene are present in 95%
of SMA carriers worldwide. We calculated the SMN1/SMN2 ratio
using multiplex PCR to determine the relative and absolute gene
dosages of the SMN1 and SMN2 genes. Genotypes of the SMN1/
SMN2 genes were scanned using DHPLC as described previously
[26,27].
Table 1. Demographic Characteristics of the 107,611 Pregnant Women Enrolled in the Study.
Year 2005 2006 2007 2008 2009 Total
Number of Pregnant Women 6,395 17,769 30,335 34,983 18,129 107,611
Age (years)
N( % )
#19 62
(0.97)
176
(0.99)
249
(0.82)
286
(0.82)
113
(0.62)
886
(0.82)
20–29 3,456
(54.04)
9,055
(50.96)
14,345
(47.29)
16,358
(46.76)
7,648
(42.19)
50,862
(47.27)
30–39 2,794
(43.69)
8,281
(46.60)
15,277
(50.36)
17,744
(50.72)
10,021
(55.28)
54,117
(50.29)
$40 83
(1.30)
257
(1.45)
464
(1.53)
595
(1.70)
347
(1.91)
1,746
(1.62)
Gestational Age
N( % )
,20 weeks 5,874
(91.85)
16,794
(94.51)
29,181
(96.20)
33,757
(96.50)
17,655
(97.39)
103,261
(95.96)
$20 weeks 521
(8.15)
975
(5.49)
1,154
(3.80)
1,226
(3.50)
474
(2.61)
4,350
(4.04)
Ethnic Origin
N( % )
Taiwanese 6,151
(96.18)
17,107
(96.27)
29,316
(96.64)
33,866
(96.81)
17,506
(96.56)
103,946
(96.59)
Non-Taiwanese 244
(3.82)
662
(3.73)
1,019
(3.36)
1,117
(3.19)
623
(3.44)
3,665
(3.41)
Residency
N( % )
Northern Taiwan 3,273
(51.18)
7,240
(40.75)
15,343
(50.55)
16,563
(47.35)
8,532
(47.06)
50,951
(47.35)
Central Taiwan 608
(9.51)
3,288
(18.50)
7,376
(24.32)
9,150
(26.16)
4,763
(26.27)
25,185
(23.40)
Southern Taiwan 2,351
(36.76)
6,706
(37.74)
6,958
(22.94)
8,739
(24.98)
4,537
(25.03)
29,291
(27.22)
Eastern Taiwan 160
(2.50)
531
(2.99)
651
(2.15)
519
(1.48)
292
(1.61)
2,153
(2.00)
Surrounding lands 3
(0.05)
4
(0.02)
7
(0.02)
12
(0.03)
5
(0.03)
31
(0.03)
Parity
N( % )
1 3,946
(61.70)
11,288
(63.53)
19,950
(65.77)
23,965
(68.50)
13,328
(73.52)
72,477
(67.35)
2 1,962
(30.68)
5,344
(30.07)
8,433
(27.80)
8,434
(24.11)
3,637
(20.06)
27,810
(25.84)
33 9 6
(6.20)
1,004
(5.65)
1,769
(5.83)
2,354
(6.73)
1,016
(5.60)
6,539
(6.08)
$49 1
(1.42)
133
(0.75)
183
(0.60)
230
(0.66)
148
(0.82)
785
(0.73)
doi:10.1371/journal.pone.0017067.t001
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A commercially available MLPA kit for SMA (SALSA P021)
was used according to the manufacturer’s protocol (MRC-
Holland, Amsterdam, The Netherlands) to confirm the genotypes
of the SMN genes. The P021 probe mix contained 37 probes
including two probes specific to exon 7 of the SMN1 and SMN2
genes (1260-L0966 and 1260-L0967), two probes specific to exon
8 of the SMN1 and SMN2 genes (1812-L1373 and 1812-L372),
four probes specific to exons 1, 4, 6 and 8 of both the SMN1 and
SMN2 genes (1814-L0807 to L0810), eight probes for genes co-
located with SMN1, and other probes for other chromosomes and
reference probes. The resulting DNA fragments were analyzed on
the Beckman CEQ-8000 Genetic Analysis System (Beckman
Coulter, Fullerton, CA, USA) with CEQ software using the D1-
labeled 600 DNA size standard (Beckman Coulter).
Classification of SMA Severity
Based on the genotype, fetuses who carried only the SMN2 gene
were classified according to risk for asymptomatic, mild, or severe
SMA. This classification was based on published studies
[11,28,29]. Severe disease was diagnosed in fetuses with one or
two SMN2 copies and mild or asymptomatic SMA was diagnosed
in fetuses with three or more copies of the SMN2 gene.
Results
First-stage: Prescreening
During the 4.5-year period (from January 2005 to June 2009),
383 clinics in 25 counties offered SMA carrier screening. DHPLC
was used as the pre-screening tool and MLPA was used for further
confirmation in cases at high risk of being a carrier. A total of
107,611 pregnant women underwent SMA screening (Table 1).
The maternal age ranged from 20 to 39 years in 98% (104,979) of
the women, and the gestational age of 96% (103,261) of the fetuses
was less than 20 weeks. The majority (67%, 72,477) of the women
were pregnant with their first child, 96% (103,946) of the women
were Taiwanese, and 47% (50,591) lived in northern Taiwan.
The detailed genotype distributions and the frequencies of the
various SMA genotypes are listed in Table 2. Among the
participants, about 90% (97,128/107,611) of the individuals with
wild type SMN1 had two copies of the gene. Only about 7%
(8,020) had three copies of the SMN1 gene, and only 0.18% (197)
of individuals had four copies of the SMN1 gene, indicating that
they had at least two SMN1 alleles on the same chromosome.
Carriers were defined as having only one copy of the SMN1 gene.
In the population we screened, 2,262 individuals were identified as
being SMA carriers. The carrier rate was 2.10%, indicating that
the carrier prevalence was about 1/48 in this study, which is lower
than the 1/40 carrier frequency for SMA reported in Western
countries [30].
The observed heterozygous SMA carrier genotypes involved
either deletion (1.18%, 1-SMN1/1-SMN2 or 1-SMN1/2-SMN2) or
conversion (0.92%, 1-SMN1/3-SMN2 or 1-SMN1/4-SMN2).
There were nine SMA carriers with one copy of SMN1 and no
copies of SMN2 (1-SMN1/0-SMN2). The average number of SMN1
alleles was 2.06 copies.
Second-Stage Screening Results
During the first-phase staging process, a total of 2,262 women
were determined to be at high risk for carrying a fetus with SMA.
Among the 2,262 partners or spouses, 224 persons refused to
participate or could not be traced because of changes in contact
information or because they worked outside the country during
the study period. During the first and second stage screenings and
genetic counseling sessions, another 47 partners or spouses were
also determined to be at high risk of being SMA carriers. The
carrier rate in the second phase was 2.31% (47/2,038). Notably,
four pregnant women were found to carry only SMN2 alleles and
no SMN1 allele (Table 2). These women had mild clinical
symptoms, such as needing assistance to stand up or climb stairs,
but were able to walk without walking aids or wheelchairs. Some
of the women accounted for their disabilities by blaming previous
traffic accidents or falls in childhood. They were not identified as
having proximal muscle weakness until they underwent the
prenatal SMA screening protocol.
Table 2. Spinal Muscular Atrophy Genotype Distribution.
Year
(month) 2005 2006 2007 2008
2009
(1–6) Total
SMN1:SMN2
0 Copies of SMN1
N( % )
1
(0.02)
0
(0)
1
(0)
1
(0)
1
(0.01)
4
(0.01)
0:2 0
(0)
0
(0)
0
(0)
0
(0)
0
(0)
0
(0)
0:3 0
(0)
0
(0)
0
(0)
0
(0)
1
(0.01)
1
(0)
0:4 1
(0.02)
0
(0)
1
(0)
1
(0)
0
(0)
3
(0)
1 Copy of SMN1
N( % )
146
(2.28)
409
(2.30)
632
(2.08)
728
(2.08)
347
(1.91)
2,262
(2.10)
1:0 2
(0.03)
0
(0)
0
(0)
3
(0.01)
4
(0.02)
9
(0.01)
1:1 17
(0.27)
53
(0.30)
94
(0.31)
100
(0.29)
49
(0.27)
313
(0.29)
1:2 58
(0.91)
157
(0.88)
279
(0.92)
319
(0.91)
140
(0.77)
953
(0.89)
1:3 69
(1.07)
198
(1.11)
258
(0.85)
303
(0.87)
153
(0.84)
981
(0.91)
1:4 0
(0)
1
(0.01)
1
(0)
3
(0.01)
1
(0.01)
6
(0.01)
2 Copies of SMN1
N( % )
5,769
(90.21)
16,039
(90.26)
27,403
(90.34)
31,525
(90.12)
16,392
(90.42)
97,128
(90.26)
2:0 245
(3.83)
605
(3.40)
1,017
(3.35)
1,178
(3.37)
586
(3.23)
3,631
(3.37)
2:1 1,771
(27.69)
5,024
(28.27)
8,599
(28.35)
9,851
(28.16)
5,172
(28.53)
30,417
(28.27)
2:2 3,643
(56.97)
10,089
(56.78)
17,196
(56.69)
19,829
(56.68)
10,278
(56.69)
61,035
(56.72)
2:3 110
(1.72)
321
(1.81)
591
(1.95)
667
(1.91)
356
(1.96)
2,045
(1.90)
3 Copies of SMN1
N( % )
472
(7.38)
1291
(7.27)
2,255
(7.43)
2,647
(7.57)
1,355
(7.47)
8,020
(7.45)
3:0 78
(1.22)
209
(1.18)
425
(1.40)
411
(1.17)
214
(1.18)
1,337
(1.24)
3:1 206
(3.22)
557
(3.13)
999
(3.29)
1,242
(3.55)
610
(3.37)
3,614
(3.36)
3:2 188
(2.94)
525
(2.96)
831
(2.74)
994
(2.84)
531
(2.93)
3,069
(2.85)
4 Copies of SMN1
N( % )
7
(0.11)
30
(0.17)
44
(0.15)
82
(0.23)
34
(0.19)
197
(0.18)
4:0 7
(0.11)
30
(0.17)
44
(0.15)
82
(0.23)
34
(0.19)
197
(0.18)
Total 6,395 17,769 30,335 34,983 18,129 107,611
doi:10.1371/journal.pone.0017067.t002
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We identified 47 carrier couples with known genotypes who
were at high risk of having SMA-affected offspring. Face-to-face
genetic counseling was done with all of these couples. Of the 47
couples, 43 women (91.49%) underwent prenatal diagnostic
procedures (CVS or amniocentesis). The results of CVS or
amniocentesis revealed that eight women were carrying fetuses
with wild-type SMN1, 23 women were carrying fetuses with SMA
carrier status, and 12 women had fetuses at high risk
for SMA. The genotypes of the couples at risk for offspring with
SMA and the genotype distributions of the screening results for
these fetuses are shown in Table 3. Previous studies have reported
that SMA genotype correlates with SMA phenotype. In the 12
affected fetuses, seven were 0-SMN1/2-SMN2, three were 0-
SMN1/3-SMN2, and two were 0-SMN1/4-SMN2. After careful
and non-directive prenatal counseling, 11 (91.67%) of the 12
pregnancies were terminated, including the five that might have
resulted in milder type II and type III phenotypes.
The outcomes of the population-based SMA screening program
in Taiwan are listed in Table 4. One infant with no SMN1 and two
SMN2 alleles was born after genetic counseling. He did not have
delayed developmental milestones initially and was cared for at
home. Limited limb movement and slight subcostal retraction
were noted at 50 days of age. Nasal flaring and abdominal
paradoxical movement developed by 82 days of age. The infant
died due to respiratory failure at 90 days of age.
Discussion
In Taiwan, it is routine for pregnant women to undergo
prenatal screening for thalassemia, but not for other single-gene
disorders, such as cystic fibrosis. The goal of carrier screening
programs for autosomal recessive diseases is to identify asymp-
tomatic carrier couples and reduce the prevalence of affected
fetuses early in pregnancy. SMA is one of the most common lethal
genetic disorders, with a carrier frequency of 1/35 to 1/50 in the
general population [31,32,33]. This carrier rate is high enough to
warrant the implementation of routine direct carrier testing and
screening programs worldwide. In Taiwan, there are approxi-
mately 200,000 pregnancies per year (Department of Health,
Taiwan). With a carrier frequency of 1 in 48, the number of
pregnancies involving a fetus at risk for SMA would be about 20
per year.
Although the American College of Medical Genetics recom-
mends routine carrier screening for SMA [1], the American
College of Obstetricians and Gynecologists does not recommend
the adoption of routine prenatal screening for SMA in the general
population because there is a lack of sufficient pilot data and lack
of data on cost effectiveness [34]. Therefore, large prospective
pilot studies of carrier screening for SMA in the general population
are needed to determine how such a program would fare.
Studies have shown that DHPLC and MLPA are reliable
methods for quantifying SMN1/SMN2 copy numbers and
determining the heterozygous status for SMN1 deletions or
conversions among carriers [20,26,27]. In our screening program,
we utilized DHPLC followed by MLPA for confirmation.
Moreover, our population-based SMA screening program allowed
carriers to make informed reproductive choices [35,36]. There-
fore, our SMA screening program fulfills many of the criteria
addressed by the American College of Obstetricians and
Gynecologists, including availability of parallel methods that are
cost-effective, highly sensitive, and highly specific. In addition,
couples were able to obtain the results of the carrier-screening
program and a prenatal diagnosis was made early in the
pregnancy. Most importantly, couples were able to participate in
well-documented genetic counseling, allowing them to become
well informed and educated during the pretest and post-test
screening stages.
In this screening program, we found that the SMN1 carrier
frequency in the Taiwan population (1 in 48) was comparable to
the ranges (1 in 35 to 50) reported in genetic epidemiological
studies in western countries and in southern Chinese populations
[23,32,37]. In our population, the genetic risk assessments for
frequency of SMN1 copies per allele were in Hardy-Weinberg
equilibrium based on our data in the general population. The
SMN1 allele frequencies were 1% for zero copies, 94.78% for one
copy, 4.2% for two copies, and 0.02% for one-copy disease. We
note three limitations of the SMA carrier-screening program that
will slightly decrease the sensitivity of the test. First, this assay does
not identify the estimated 0.084% of carriers with two copies of
SMN1 on a single chromosome and no copies on the second
chromosome, which is defined as ‘‘2+0’’ carriers [25,38]. This is a
major source of false-negative screening outcomes. Individuals
with two copies of SMN1 on one chromosome are at a 50% risk for
having offspring that inherit an allele without a functional SMN1
gene. The prior and adjusted carrier rates in our population were
approximately 1:49 and 1:738, respectively, which are similar to
the prior and adjusted carrier rates reported previously [23].
Second, 2% of SMA cases arise as a result of de novo mutation
events [11,38,39]. Third, 1.7% of carriers could have intragenic
mutations in others exons of the SMN1 gene [25]. False-negatives
can occur based these situations. The negative predictive value of
DHPLC coupled with MLPA is 99.87% and the combined
method can detect 93.88% of carriers since most of the cases result
from a common single deletion event [40].
Genetic counseling is very important for the SMA target group.
Couples must receive adequate and balanced information during
Table 3. Genotypes of Couples at Risk for Offspring with
Spinal Muscular Atrophy.
Offspring Genotype
Copy no. of genes N
Parental Genotype
Copy no. of
SMN1/SMN2 genes
Pregnancies
Terminated
0-SMN1/2-SMN2 3 1/1 1/2 2
4 1/2 1/2 4
0-SMN1/3-SMN2 3 1/2 1/3 3
0-SMN1/4-SMN2 2 1/3 1/3 2
1-SMN1/1-SMN2 1 1/1 1/2 0
1 1/1 1/3 0
1 1/2 1/2 0
1-SMN1/2-SMN2 1 1/2 1/2 0
3 1/2 1/3 0
1-SMN1/3-SMN2 3 1/1 1/3 0
7 1/2 1/3 0
6 1/3 1/3 0
2-SMN1/2-SMN2 2 1/1 1/2 0
1 1/1 1/3 0
3 1/2 1/2 0
1 1/2 1/3 0
1 1/3 1/3 0
Total 43 11
doi:10.1371/journal.pone.0017067.t003
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counseling during the pretest process comprises providing
information about the disease, the carrier frequency, inheritance
patterns, prediction of severity, and relevant aspects of test
performance. This information is provided on a fact sheet and
brochure. Specifically, genetic counseling addresses the limitations
of dosage testing and the possibility of false-negative results.
Genetic screening programs, however, present ethical dilem-
mas. Although SMA is not a disease that causes mental disability,
individuals with SMA can suffer from severely progressive and life-
threatening muscular disabilities. Gene dosage analyses have
revealed that there is an inverse relationship between the number
of SMN2 gene copies and severity of SMA [12]. However, a major
issue of carrier screening is that one cannot predict the phenotype
from carrier testing. When two carriers are identified, it is not
possible to inform them what type of offspring they are at risk of
having. This is a major limitation of testing. There are several
reports of individuals with homozygous deletion of the SMN1 gene
who were asymptomatic 0-SMN1/4-SMN2 because of the presence
of other modifying genes [13,41,42]. After non-directive and non-
judgmental counseling, the couples with the affected SMA fetuses
chose to terminate the pregnancies despite the clinical subtype.
The high termination rate in Taiwan may due to religiosity or
social mores. Moreover, it may be an indication of how parents
feel about having a child affected with SMA, regardless of the
phenotype.
Because SMA is present in all populations, carrier testing should
be offered to all couples regardless of race or ethnicity. Analyses of
larger populations in different countries are needed to evaluate the
benefit and the effectiveness of each screening program. Our study
is, so far, the largest scale study to evaluate the outcomes of a
nationwide, population-based screening program for SMA. Our
results suggest that SMA carrier screening should be integrated
into global prenatal care.
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